348 related articles for article (PubMed ID: 16874798)
21. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
23. NSAIDs-induced gastrointestinal damage. Review.
Arroyo M; Lanas A
Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
[TBL] [Abstract][Full Text] [Related]
24. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands.
Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC
Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790
[TBL] [Abstract][Full Text] [Related]
26. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
Cibere J; Sibley JT; Haga M
J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
[TBL] [Abstract][Full Text] [Related]
27. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Lelorier J
J Rheumatol; 2006 Mar; 33(3):588-96. PubMed ID: 16463432
[TBL] [Abstract][Full Text] [Related]
28. The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
Patino FG; Allison J; Olivieri J; Mudano A; Juarez L; Person S; Mikuls TR; Moreland L; Kovac SH; Saag KG
Arthritis Rheum; 2003 Jun; 49(3):293-9. PubMed ID: 12794782
[TBL] [Abstract][Full Text] [Related]
29. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
Cox ER; Motheral B; Mager D
Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users.
Abraham NS; Hartman C; Castillo D; Richardson P; Smalley W
Am J Gastroenterol; 2008 Feb; 103(2):323-32. PubMed ID: 18289200
[TBL] [Abstract][Full Text] [Related]
31. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada.
Hartnell NR; Flanagan PS; MacKinnon NJ; Bakowsky VS
Am J Geriatr Pharmacother; 2004 Sep; 2(3):171-80. PubMed ID: 15561649
[TBL] [Abstract][Full Text] [Related]
32. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
33. Upper gastrointestinal symptoms and therapies in elderly out-patients, users of non-selective NSAIDs or coxibs.
Pilotto A; Franceschi M; Vitale DF; Zaninelli A; Masotti G; Rengo F; ;
Aliment Pharmacol Ther; 2005 Jul; 22(2):147-55. PubMed ID: 16011673
[TBL] [Abstract][Full Text] [Related]
34. Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness.
Targownik LE; Thomson PA
Can Fam Physician; 2006 Sep; 52(9):1100-5. PubMed ID: 17279220
[TBL] [Abstract][Full Text] [Related]
35. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
36. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Chan FK
Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
[TBL] [Abstract][Full Text] [Related]
37. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs.
Smalley W; Stein CM; Arbogast PG; Eisen G; Ray WA; Griffin M
Arthritis Rheum; 2002 Aug; 46(8):2195-200. PubMed ID: 12209525
[TBL] [Abstract][Full Text] [Related]
38. Adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment and the risk of upper gastrointestinal tract events: a population-based study.
Valkhoff VE; van Soest EM; Mazzaglia G; Molokhia M; Schade R; Trifiro G; Goldstein JL; Hernandez-Diaz S; Kuipers EJ; Sturkenboom MC
Arthritis Rheum; 2012 Aug; 64(8):2792-802. PubMed ID: 22508379
[TBL] [Abstract][Full Text] [Related]
39. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
Lanas A; Hunt R
Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
[TBL] [Abstract][Full Text] [Related]
40. Co-prescription of gastroprotective agents in patients taking non-selective NSAIDs or COX-2 selective inhibitors: analysis of prescriptions.
Pasina L; Nobili A; Tettamanti M; Riva E; Lucca U; Piccinelli R; Defendi L; Perego L; Lucifora S; Bulla C
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):735-43. PubMed ID: 20979932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
